.png){kind=icon}
.png){kind=icon}
Return
Pre-Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long-Term Albumin in Patients With Cirrhosis and Ascites
.png){kind=icon}
OA
AI
E
G
S
S
C
S
F
F
A
L
G
S
F
R
G
M
O
P
M
M
P
F
DOI：10.1002/ueg2.70258.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The benefit of long-term albumin (LTA) in improving survival and reducing complications in patients with cirrhosis and ascites is not consistently observed across studies, possibly reflecting differences in patient populations and treatment regimens. This study aimed to determine whether baseline serum albumin (SA) levels can predict which patients are most likely to benefit from LTA therapy.
Keywords:
decompensated cirrhosis
paracentesis
randomized controlled trial
refractory ascites
survival
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
6.7
Papers:
1.9K
Citations:
4.9K
Organization
Cited Papers